MET and neoplasm: Clinical heterogeneity might result from the different patients (with different age, tumor size, clinical stage, ethnicity, physical condition, etc.), diverse treatment types, various treatment protocols, different dosages and drug types, etc. Moreover, differences in primary antibodies, IHC staining protocols, evaluation standards, and cut-off values for high MET expression might also contribute to heterogeneity.